Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 753 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: End-Stage Kidney Disease Clear all
Completed No phase listed Observational

Mapping Multidimensional Illness Trajectories of Patients With End-stage Kidney Disease

NCT01530945
View directory record Official record
Conditions
End Stage Kidney Disease
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 3, 2015 · Synced Jul 23, 2026, 6:22 AM EDT
Completed Not applicable Interventional

Treatment Choice and Outcomes for ESRD: Evidence From the First Year of a Nationwide Randomized Evaluation

NCT05005572
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Payment adjustment for home dialysis and transplant
Other
Lead sponsor
Amy Finkelstein
Other
Eligibility
66 Years and older
Enrollment
18,621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Jul 23, 2026, 6:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis

NCT05099445
View directory record Official record
Conditions
Renal Impairment, Hemodialysis
Interventions
INCB000928
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 82 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
5
States / cities
Rialto, California • Hialeah, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated May 14, 2023 · Synced Jul 23, 2026, 6:22 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of AB023 (Xisomab 3G3) in End Stage Renal Disease Patients on Chronic Hemodialysis

NCT03612856
View directory record Official record
Conditions
End Stage Renal Disease, Thrombosis
Interventions
AB023- Dose 1, AB023-Dose 2, placebo
Drug
Lead sponsor
Aronora, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Jul 23, 2026, 6:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Safety Study of Tocilizumab to Improve Transplant Rates in Highly Sensitized Patients Awaiting Kidney Transplantation

NCT01594424
View directory record Official record
Conditions
End Stage Renal Disease (ESRD)
Interventions
Tocilizumab, Intravenous Immunoglobulin
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2016 · Synced Jul 23, 2026, 6:22 AM EDT
Withdrawn No phase listed Observational

Inflammation in Peritoneal Dialysis Patients: Effect of Obesity

NCT01691196
View directory record Official record
Conditions
End-Stage Renal Disease, Renal Disease, End-Stage, Renal Failure, End-Stage, Obesity
Interventions
Not listed
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 28, 2019 · Synced Jul 23, 2026, 6:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

NCT05624710
View directory record Official record
Conditions
Renal Insufficiency, Kidney Diseases
Interventions
INCB054707
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Tustin, California • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Jul 23, 2026, 6:22 AM EDT
Withdrawn Not applicable Interventional

Animal Assisted Intervention for Hemodialysis Outpatients

NCT06030050
View directory record Official record
Conditions
End-Stage Kidney Disease, Chronic Kidney Failure, Chronic Pain
Interventions
Animal-assisted intervention
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Jul 23, 2026, 6:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety of Fevipiprant in Patients With Renal Impairment Compared to Matched Healthy Subjects

NCT03087942
View directory record Official record
Conditions
Renal Insufficiency
Interventions
QAW039, QAW39A, QAW39A2107
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Jul 23, 2026, 6:22 AM EDT
Completed Phase 4 Interventional

Effect of Paricalcitol on Markers of Inflammation in Hemodialysis Patients

NCT00294866
View directory record Official record
Conditions
Kidney Failure
Interventions
Paricalcitol
Drug
Lead sponsor
Fresenius Medical Care North America
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
6
States / cities
Evergreen Park, Illinois • Kalamazoo, Michigan • West Orange, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2010 · Synced Jul 23, 2026, 6:22 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects

NCT00888069
View directory record Official record
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism, Chronic Renal Insufficiency, Chronic Renal Failure
Interventions
CTAP101 Capsules, CTAP101 Injection
Drug
Lead sponsor
OPKO IP Holdings II, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
12
States / cities
Peoria, Arizona • Evergreen Park, Illinois • Springfield, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2014 · Synced Jul 23, 2026, 6:22 AM EDT
Completed Not applicable Interventional

Resistance Training During Maintenance Dialysis

NCT00363961
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Resistance exercise
Behavioral
Lead sponsor
Tufts University
Other
Eligibility
30 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 9, 2009 · Synced Jul 23, 2026, 6:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Fructose on Blood Fats in Dialysis Patients and Healthy Volunteers

NCT00234156
View directory record Official record
Conditions
End-stage Renal Disease
Interventions
oral fructose and high fat diet
Procedure
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2012 · Synced Jul 23, 2026, 6:22 AM EDT
Active, not recruiting Not applicable Interventional

Light Therapy in End Stage Kidney Disease

NCT06310161
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Bright light, Dim Light
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 23, 2026, 6:22 AM EDT
Completed Phase 2Phase 3 Interventional

Communication During Hospitalization About Resuscitation Trial

NCT02984124
View directory record Official record
Conditions
Severe Life-limiting COPD, Severe Life-limiting Heart Failure, Severe Life-limiting Cirrhosis, Severe Life-limiting Malignancy, Severe Functional Impairment, End Stage Renal Disease
Interventions
Informed Assent Discussion, Usual Care with Attention Control
Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
65 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
4
States / cities
Chapel Hill, North Carolina • Charleston, South Carolina • Burlington, Vermont + 1 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 23, 2026, 6:22 AM EDT
Completed No phase listed Observational

Observational Study of Kibow Biotics in Dialysis Patients

NCT01450670
View directory record Official record
Conditions
Chronic Kidney Failure
Interventions
Kibow Biotics
Dietary Supplement
Lead sponsor
Kibow Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Jul 23, 2026, 6:22 AM EDT
Not listed Phase 1 Interventional

Use of Direct Peritoneal Resuscitation in High-risk Liver Transplant Recipients

NCT05195125
View directory record Official record
Conditions
End Stage Liver DIsease, Obesity, Acute Kidney Injury
Interventions
Direct Peritoneal Resuscitation
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Jul 23, 2026, 6:22 AM EDT
Completed Phase 3 Interventional

Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2

NCT05836220
View directory record Official record
Conditions
Secondary Hyperparathyroidism, End Stage Kidney Disease
Interventions
PLS240, Placebo, Open-Label Extension PLS240
Drug
Lead sponsor
Pathalys Pharma
Industry
Eligibility
18 Years to 80 Years
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
50
States / cities
Anaheim, California • Chula Vista, California • Escondido, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Jul 23, 2026, 6:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment

NCT07165015
View directory record Official record
Conditions
Renal Impairment, Healthy, Renal Insufficiency, End Stage Renal Disease (ESRD)
Interventions
LY3537031
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Orlando, Florida • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Jul 23, 2026, 6:22 AM EDT
Completed Not applicable Interventional Results available

Post-Approval Study for the FLAIR Endovascular Stent Graft

NCT00677235
View directory record Official record
Conditions
Stenosis of Vascular Prosthetic Devices, Implants and Grafts
Interventions
FLAIR Endovascular Stent Graft, PTA
Device · Procedure
Lead sponsor
C. R. Bard
Industry
Eligibility
21 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Bamberg, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Jul 23, 2026, 6:22 AM EDT
Completed Phase 3 Interventional

Homocysteine Study (HOST)

NCT00032435
View directory record Official record
Conditions
End Stage Renal Disease, Renal Failure
Interventions
PAL-40 Active, PAL-40 Placebo
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
21 Years and older
Enrollment
2,003 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
36
States / cities
Birmingham, Alabama • Menlo Park, California • Palo Alto, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2010 · Synced Jul 23, 2026, 6:22 AM EDT
Completed Phase 1 Interventional Results available

A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011)

NCT05656040
View directory record Official record
Conditions
End-Stage Renal Disease, End-Stage Kidney Disease, Kidney Failure, Chronic
Interventions
MK-2060, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Edgewater, Florida • Miami, Florida • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Jul 23, 2026, 6:22 AM EDT
Not listed No phase listed Observational

Impact of IDPN on Nutrition Markers in Patients Receiving ICHD

NCT05439174
View directory record Official record
Conditions
End-stage Renal Disease, Malnutrition; Protein
Interventions
Intradialytic Parenteral Nutrition
Other
Lead sponsor
Patient Care America
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Pompano Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Jul 23, 2026, 6:22 AM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients

NCT01435174
View directory record Official record
Conditions
End-stage Renal Disease, Cardiovascular Disease
Interventions
Ranolazine, Pharmacokinetic Blood and Dialysate Sampling, QT Interval
Drug · Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 74 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 15, 2017 · Synced Jul 23, 2026, 6:22 AM EDT